Pulmonx (LUNG) Financials

$3.35 +0.01 (+0.30%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Pulmonx

This table shows Pulmonx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-56	-61	-59
Consolidated Net Income / (Loss)	-56	-61	-59
Net Income / (Loss) Continuing Operations	-56	-61	-59
Total Pre-Tax Income	-56	-60	-59
Total Operating Income	-58	-62	-59
Total Gross Profit	62	51	40
Total Revenue	84	69	54
Operating Revenue	84	69	54
Total Cost of Revenue	22	18	14
Operating Cost of Revenue	22	18	14
Total Operating Expenses	120	113	99
Selling, General & Admin Expense	102	95	83
Research & Development Expense	18	18	15
Total Other Income / (Expense), net	1.81	1.66	0.07
Interest Expense	3.51	3.23	1.07
Interest & Investment Income	5.06	5.57	1.53
Other Income / (Expense), net	0.26	-0.67	-0.40
Income Tax Expense	0.50	0.57	0.35
Basic Earnings per Share	($1.44)	($1.60)	($1.59)
Weighted Average Basic Shares Outstanding	39.11M	37.97M	37.10M
Diluted Earnings per Share	($1.44)	($1.60)	($1.59)
Weighted Average Diluted Shares Outstanding	39.11M	37.97M	37.10M
Weighted Average Basic & Diluted Shares Outstanding	39.80M	38.54M	37.65M

This table shows Pulmonx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Consolidated Net Income / (Loss)	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Net Income / (Loss) Continuing Operations	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Total Pre-Tax Income	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Total Operating Income	-13	-14	-16	-15	-14	-15	-16	-16	-15	-14
Total Gross Profit	18	15	15	14	14	13	13	11	11	10
Total Revenue	24	20	21	19	19	18	17	15	15	14
Operating Revenue	24	20	21	19	19	18	17	15	15	14
Total Cost of Revenue	6.18	5.36	5.48	4.78	4.88	4.64	4.46	3.95	4.24	3.35
Operating Cost of Revenue	6.18	5.36	5.48	4.78	4.88	4.64	4.46	3.95	4.24	3.35
Total Operating Expenses	31	29	31	29	28	28	29	27	26	24
Selling, General & Admin Expense	27	25	25	24	24	24	23	23	22	20
Research & Development Expense	4.00	3.74	5.62	4.21	3.90	4.22	5.71	4.25	3.90	4.37
Total Other Income / (Expense), net	0.28	0.18	0.38	0.97	0.28	0.34	0.38	0.66	0.59	-0.24
Interest Expense	0.84	0.89	0.89	0.88	0.90	0.89	0.86	0.57	0.36	0.29
Interest & Investment Income	1.05	1.27	1.31	1.44	1.54	1.49	1.41	1.13	0.75	0.48
Other Income / (Expense), net	0.08	-0.20	-0.04	0.42	-0.36	-0.26	-0.16	0.11	0.20	-0.43
Income Tax Expense	0.04	0.19	0.08	0.19	0.25	0.06	0.14	0.12	0.25	0.00
Basic Earnings per Share	($0.33)	($0.36)	($0.39)	($0.36)	($0.36)	($0.39)	($0.43)	($0.42)	($0.38)	($0.38)
Weighted Average Basic Shares Outstanding	39.11M	39.28M	38.94M	38.64M	37.97M	38.12M	37.82M	37.57M	37.10M	37.19M
Diluted Earnings per Share	($0.33)	($0.36)	($0.39)	($0.36)	($0.36)	($0.39)	($0.43)	($0.42)	($0.38)	($0.38)
Weighted Average Diluted Shares Outstanding	39.11M	39.28M	38.94M	38.64M	37.97M	38.12M	37.82M	37.57M	37.10M	37.19M
Weighted Average Basic & Diluted Shares Outstanding	39.80M	39.49M	39.15M	38.82M	38.54M	38.31M	38.03M	37.75M	37.65M	37.41M

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-13	-18	-47
Net Cash From Operating Activities	-32	-38	-45
Net Cash From Continuing Operating Activities	-32	-38	-45
Net Income / (Loss) Continuing Operations	-56	-61	-59
Consolidated Net Income / (Loss)	-56	-61	-59
Depreciation Expense	1.49	1.55	1.51
Amortization Expense	-1.56	-0.98	-0.15
Non-Cash Adjustments To Reconcile Net Income	27	25	19
Changes in Operating Assets and Liabilities, net	-1.70	-2.56	-7.01
Net Cash From Investing Activities	17	-2.01	-4.23
Net Cash From Continuing Investing Activities	17	-2.01	-4.23
Purchase of Property, Plant & Equipment	-1.45	-0.81	-1.32
Purchase of Investments	-28	-46	-47
Sale and/or Maturity of Investments	47	45	44
Net Cash From Financing Activities	1.36	21	2.42
Net Cash From Continuing Financing Activities	1.36	21	2.42
Repayment of Debt	-0.10	-0.09	-0.14
Issuance of Debt	0.00	20	0.00
Issuance of Common Equity	1.24	1.18	1.94
Other Financing Activities, net	0.22	0.31	0.64
Effect of Exchange Rate Changes	0.08	0.03	0.15
Cash Interest Paid	3.48	2.98	0.85
Cash Income Taxes Paid	0.56	0.47	0.40

This table details how cash moves in and out of Pulmonx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	7.59	-0.15	-6.67	-13	-11	-6.87	-8.59	8.67	-11	-9.55
Net Cash From Operating Activities	-6.73	-7.24	-5.77	-12	-8.45	-8.63	-7.89	-13	-9.81	-11
Net Cash From Continuing Operating Activities	-6.73	-7.24	-5.77	-12	-8.45	-8.63	-7.89	-13	-9.81	-11
Net Income / (Loss) Continuing Operations	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Consolidated Net Income / (Loss)	-13	-14	-15	-14	-14	-15	-16	-16	-14	-14
Depreciation Expense	0.29	0.38	0.40	0.42	0.29	0.42	0.41	0.44	0.39	0.38
Amortization Expense	-0.33	-0.39	-0.46	-0.38	-0.31	-0.25	-0.22	-0.19	-0.14	-0.06
Non-Cash Adjustments To Reconcile Net Income	5.69	6.10	8.31	6.54	5.89	7.13	6.64	5.57	5.05	5.21
Changes in Operating Assets and Liabilities, net	0.79	0.83	1.31	-4.63	-0.42	-1.02	1.48	-2.59	-0.82	-2.05
Net Cash From Investing Activities	14	6.75	-0.84	-2.51	-2.76	0.99	-0.81	0.57	-0.73	0.04
Net Cash From Continuing Investing Activities	14	6.75	-0.84	-2.51	-2.76	0.99	-0.81	0.57	-0.73	0.04
Purchase of Property, Plant & Equipment	-0.11	-0.42	-0.47	-0.45	-0.20	-0.49	-0.05	-0.06	-0.18	-0.28
Purchase of Investments	-1.49	-5.58	-7.03	-14	-4.81	-16	-13	-13	-10	-15
Sale and/or Maturity of Investments	16	13	6.67	12	2.25	17	12	14	9.75	15
Net Cash From Financing Activities	0.06	0.46	-0.02	0.86	0.02	0.57	0.09	21	0.07	0.91
Net Cash From Continuing Financing Activities	0.06	0.46	-0.02	0.86	0.02	0.57	0.09	21	0.07	0.91
Repayment of Debt	-0.05	-	-	-	-0.05	-	-	-	-0.10	-
Issuance of Common Equity	0.00	0.43	-	0.81	-	0.51	-	0.68	-	0.83
Other Financing Activities, net	0.11	0.03	0.02	0.06	0.06	0.06	0.14	0.04	0.19	0.07
Effect of Exchange Rate Changes	0.19	-0.12	-0.05	0.05	-0.21	0.20	0.02	0.02	-0.20	0.19
Cash Interest Paid	0.82	0.88	0.90	0.88	0.88	0.87	0.88	0.36	0.22	0.25
Cash Income Taxes Paid	0.10	0.19	0.11	0.17	0.10	0.16	0.11	0.09	0.06	0.11

This table presents Pulmonx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	163	178	194
Total Current Assets	136	150	169
Cash & Equivalents	71	84	102
Restricted Cash	0.26	0.24	0.23
Short-Term Investments	31	34	39
Accounts Receivable	13	12	8.68
Inventories, net	17	17	15
Prepaid Expenses	4.47	4.24	4.34
Plant, Property, & Equipment, net	2.91	4.03	4.69
Total Noncurrent Assets	24	23	20
Long-Term Investments	0.00	14	5.92
Goodwill	2.33	2.33	2.33
Intangible Assets	0.00	0.03	0.15
Other Noncurrent Operating Assets	21	6.58	12
Total Liabilities & Shareholders' Equity	163	178	194
Total Liabilities	77	59	40
Total Current Liabilities	24	23	18
Short-Term Debt	3.18	2.16	0.09
Accounts Payable	3.83	1.50	1.76
Accrued Expenses	16	16	13
Current Deferred Revenue	0.14	0.10	0.12
Current Deferred & Payable Income Tax Liabilities	0.05	0.09	0.02
Other Current Liabilities	0.78	3.07	3.23
Total Noncurrent Liabilities	53	36	21
Long-Term Debt	34	35	17
Noncurrent Deferred & Payable Income Tax Liabilities	0.09	0.11	0.09
Other Noncurrent Operating Liabilities	19	1.11	3.85
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	86	118	154
Total Preferred & Common Equity	86	118	154
Preferred Stock	0.00	0.00	0.00
Total Common Equity	86	118	154
Common Stock	551	527	503
Retained Earnings	-468	-411	-350
Accumulated Other Comprehensive Income / (Loss)	2.11	2.64	1.58

This table presents Pulmonx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	167	173	165	185	193	201	202
Total Current Assets	141	146	148	147	164	181	183
Cash & Equivalents	63	63	70	95	102	110	112
Restricted Cash	0.26	0.26	0.24	0.24	0.47	0.23	0.23
Short-Term Investments	44	51	46	22	34	42	44
Accounts Receivable	12	11	11	10	8.94	8.17	7.22
Inventories, net	17	17	17	16	16	16	16
Prepaid Expenses	4.26	3.30	3.82	4.42	4.23	4.47	3.19
Plant, Property, & Equipment, net	2.98	2.83	4.22	4.07	4.22	4.49	4.92
Total Noncurrent Assets	23	24	12	34	24	15	14
Long-Term Investments	0.00	0.00	4.29	23	12	2.64	0.00
Goodwill	2.33	2.33	2.33	2.33	2.33	2.33	2.33
Intangible Assets	0.00	0.00	0.00	0.06	0.09	0.12	0.19
Other Noncurrent Operating Assets	21	21	5.80	7.92	9.59	10	12
Total Liabilities & Shareholders' Equity	167	173	165	185	193	201	202
Total Liabilities	73	71	54	59	59	57	39
Total Current Liabilities	18	16	21	20	20	17	22
Short-Term Debt	0.10	0.09	5.23	0.09	0.09	0.09	5.04
Accounts Payable	4.58	3.18	3.13	3.19	2.38	2.89	2.65
Accrued Expenses	13	12	10	14	14	11	11
Current Deferred Revenue	0.11	0.11	0.11	0.09	0.10	0.11	0.11
Current Deferred & Payable Income Tax Liabilities	0.07	0.07	0.07	0.00	0.04	0.06	0.00
Other Current Liabilities	0.66	1.07	2.69	3.44	3.35	3.30	3.15
Total Noncurrent Liabilities	55	55	33	39	40	40	17
Long-Term Debt	37	37	32	37	37	37	12
Noncurrent Deferred & Payable Income Tax Liabilities	0.13	0.12	0.14	0.10	0.09	0.07	0.05
Other Noncurrent Operating Liabilities	18	18	0.65	1.54	2.40	3.02	4.64
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	94	101	110	126	134	144	163
Total Preferred & Common Equity	94	101	110	126	134	144	163
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	94	101	110	126	134	144	163
Common Stock	546	539	533	521	514	508	498
Retained Earnings	-454	-440	-425	-397	-382	-366	-336
Accumulated Other Comprehensive Income / (Loss)	2.53	1.97	1.96	1.94	1.96	1.82	1.40

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	22.01%	27.98%	10.84%
EBITDA Growth	7.28%	-7.58%	-23.07%
EBIT Growth	8.24%	-6.06%	-23.27%
NOPAT Growth	6.83%	-5.62%	-23.96%
Net Income Growth	7.31%	-3.26%	-21.09%
EPS Growth	10.00%	-0.63%	-17.78%
Operating Cash Flow Growth	16.15%	16.58%	-8.93%
Free Cash Flow Firm Growth	12.37%	5.10%	-10.83%
Invested Capital Growth	-10.84%	-0.87%	22.52%
Revenue Q/Q Growth	5.66%	5.94%	3.31%
EBITDA Q/Q Growth	1.59%	-0.20%	-3.30%
EBIT Q/Q Growth	1.60%	0.24%	-2.92%
NOPAT Q/Q Growth	0.86%	1.13%	-4.01%
Net Income Q/Q Growth	1.25%	0.65%	-2.22%
EPS Q/Q Growth	2.04%	1.23%	-1.27%
Operating Cash Flow Q/Q Growth	5.17%	3.48%	1.97%
Free Cash Flow Firm Q/Q Growth	7.49%	-0.08%	0.47%
Invested Capital Q/Q Growth	-8.11%	3.61%	1.28%
Profitability Metrics	-	-	-
Gross Margin	74.00%	73.90%	74.29%
EBITDA Margin	-68.65%	-90.33%	-107.47%
Operating Margin	-68.87%	-90.19%	-109.27%
EBIT Margin	-68.56%	-91.17%	-110.01%
Profit (Net Income) Margin	-67.30%	-88.60%	-109.80%
Tax Burden Percent	100.89%	100.95%	100.60%
Interest Burden Percent	97.29%	96.27%	99.22%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-179.21%	-181.14%	-188.03%
ROIC Less NNEP Spread (ROIC-NNEP)	-159.09%	-165.56%	-176.26%
Return on Net Nonoperating Assets (RNNOA)	123.96%	136.46%	154.10%
Return on Equity (ROE)	-55.25%	-44.68%	-33.94%
Cash Return on Invested Capital (CROIC)	-167.76%	-180.27%	-208.27%
Operating Return on Assets (OROA)	-33.73%	-33.71%	-27.53%
Return on Assets (ROA)	-33.11%	-32.76%	-27.48%
Return on Common Equity (ROCE)	-55.25%	-44.68%	-33.94%
Return on Equity Simple (ROE_SIMPLE)	-65.72%	-51.42%	-38.26%
Net Operating Profit after Tax (NOPAT)	-40	-43	-41
NOPAT Margin	-48.21%	-63.13%	-76.49%
Net Nonoperating Expense Percent (NNEP)	-20.12%	-15.58%	-11.78%
Return On Investment Capital (ROIC_SIMPLE)	-32.84%	-27.87%	-
Cost of Revenue to Revenue	26.00%	26.10%	25.71%
SG&A Expenses to Revenue	121.90%	137.76%	154.87%
R&D to Revenue	20.97%	26.33%	28.69%
Operating Expenses to Revenue	142.86%	164.09%	183.56%
Earnings before Interest and Taxes (EBIT)	-57	-63	-59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-58	-62	-58
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	3.12	4.13	2.05
Price to Tangible Book Value (P/TBV)	3.21	4.21	2.08
Price to Revenue (P/Rev)	3.20	7.11	5.88
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.58	16.53	7.71
Enterprise Value to Revenue (EV/Rev)	2.43	5.74	3.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.43	0.31	0.11
Long-Term Debt to Equity	0.40	0.30	0.11
Financial Leverage	-0.78	-0.82	-0.87
Leverage Ratio	1.67	1.36	1.24
Compound Leverage Factor	1.62	1.31	1.23
Debt to Total Capital	30.23%	23.94%	10.11%
Short-Term Debt to Total Capital	2.58%	1.39%	0.05%
Long-Term Debt to Total Capital	27.65%	22.56%	10.06%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.77%	76.06%	89.89%
Debt to EBITDA	-0.65	-0.60	-0.30
Net Debt to EBITDA	1.12	1.52	2.25
Long-Term Debt to EBITDA	-0.59	-0.57	-0.30
Debt to NOPAT	-0.92	-0.86	-0.42
Net Debt to NOPAT	1.60	2.18	3.17
Long-Term Debt to NOPAT	-0.84	-0.81	-0.42
Altman Z-Score	-1.76	1.77	2.44
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.58	6.50	9.14
Quick Ratio	4.69	5.58	8.10
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-38	-43	-45
Operating Cash Flow to CapEx	-2,179.47%	-4,660.47%	-3,420.56%
Free Cash Flow to Firm to Interest Expense	-10.78	-13.35	-42.65
Operating Cash Flow to Interest Expense	-8.99	-11.64	-42.29
Operating Cash Flow Less CapEx to Interest Expense	-9.41	-11.89	-43.53
Efficiency Ratios	-	-	-
Asset Turnover	0.49	0.37	0.25
Accounts Receivable Turnover	6.64	6.61	7.04
Inventory Turnover	1.29	1.15	0.89
Fixed Asset Turnover	24.16	15.75	11.29
Accounts Payable Turnover	8.18	11.01	8.26
Days Sales Outstanding (DSO)	54.94	55.23	51.83
Days Inventory Outstanding (DIO)	281.93	318.78	408.06
Days Payable Outstanding (DPO)	44.59	33.14	44.18
Cash Conversion Cycle (CCC)	292.27	340.87	415.70
Capital & Investment Metrics	-	-	-
Invested Capital	21	24	24
Invested Capital Turnover	3.72	2.87	2.46
Increase / (Decrease) in Invested Capital	-2.58	-0.21	4.42
Enterprise Value (EV)	204	394	185
Market Capitalization	268	488	315
Book Value per Share	$2.17	$3.09	$4.12
Tangible Book Value per Share	$2.11	$3.03	$4.05
Total Capital	123	156	171
Total Debt	37	37	17
Total Long-Term Debt	34	35	17
Net Debt	-65	-94	-130
Capital Expenditures (CapEx)	1.45	0.81	1.32
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	12	9.18
Debt-free Net Working Capital (DFNWC)	115	129	151
Net Working Capital (NWC)	112	127	150
Net Nonoperating Expense (NNE)	16	17	18
Net Nonoperating Obligations (NNO)	-65	-94	-130
Total Depreciation and Amortization (D&A)	-0.07	0.57	1.37
Debt-free, Cash-free Net Working Capital to Revenue	15.81%	17.59%	17.11%
Debt-free Net Working Capital to Revenue	137.23%	188.45%	280.55%
Net Working Capital to Revenue	133.44%	185.31%	280.39%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.44)	($1.60)	($1.59)
Adjusted Weighted Average Basic Shares Outstanding	39.11M	37.97M	37.10M
Adjusted Diluted Earnings per Share	($1.44)	($1.60)	($1.59)
Adjusted Weighted Average Diluted Shares Outstanding	39.11M	37.97M	37.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.80M	38.54M	37.65M
Normalized Net Operating Profit after Tax (NOPAT)	-40	-43	-41
Normalized NOPAT Margin	-48.21%	-63.13%	-76.49%
Pre Tax Income Margin	-66.71%	-87.76%	-109.15%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-16.38	-19.37	-55.38
NOPAT to Interest Expense	-11.52	-13.41	-38.50
EBIT Less CapEx to Interest Expense	-16.79	-19.62	-56.61
NOPAT Less CapEx to Interest Expense	-11.93	-13.66	-39.74
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-0.05%

This table displays calculated financial ratios and metrics derived from Pulmonx's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.28%	15.39%	20.87%	29.71%	24.98%	30.85%	23.25%	34.77%	12.53%	1.82%
EBITDA Growth	6.49%	6.05%	4.22%	12.29%	-0.88%	-8.77%	-15.69%	-5.16%	-14.93%	-43.61%
EBIT Growth	6.56%	7.18%	5.69%	13.33%	1.03%	-7.48%	-13.89%	-3.98%	-13.15%	-43.21%
NOPAT Growth	3.61%	6.90%	4.97%	11.37%	4.83%	-8.94%	-14.07%	-4.67%	-18.28%	-42.71%
Net Income Growth	5.13%	5.07%	5.37%	13.31%	2.77%	-5.14%	-10.62%	-0.20%	-9.82%	-39.20%
EPS Growth	8.33%	7.69%	9.30%	14.29%	5.26%	-2.63%	-7.50%	2.33%	-5.56%	-35.71%
Operating Cash Flow Growth	20.35%	16.04%	26.88%	6.71%	13.84%	19.29%	17.49%	15.85%	8.45%	-28.53%
Free Cash Flow Firm Growth	28.59%	-1.30%	5.51%	16.62%	34.94%	38.08%	29.40%	35.04%	11.53%	3.94%
Invested Capital Growth	-10.84%	0.54%	2.01%	6.19%	-0.87%	-3.10%	2.47%	11.42%	22.52%	35.48%
Revenue Q/Q Growth	16.57%	-1.91%	10.23%	-2.20%	9.11%	2.76%	18.29%	-5.77%	14.24%	-3.21%
EBITDA Q/Q Growth	6.78%	8.73%	-11.69%	1.59%	6.34%	6.96%	-2.28%	-13.19%	-0.98%	1.04%
EBIT Q/Q Growth	6.91%	8.48%	-10.88%	1.09%	7.52%	7.01%	-1.90%	-12.94%	-0.44%	1.46%
NOPAT Q/Q Growth	5.04%	9.56%	-7.47%	-4.43%	8.28%	7.68%	-0.24%	-12.12%	-5.00%	3.33%
Net Income Q/Q Growth	6.85%	7.71%	-11.47%	1.00%	6.79%	8.00%	-2.11%	-11.04%	-0.78%	3.20%
EPS Q/Q Growth	8.33%	7.69%	-8.33%	0.00%	7.69%	9.30%	-2.38%	-10.53%	0.00%	5.00%
Operating Cash Flow Q/Q Growth	7.07%	-25.51%	51.08%	-39.60%	2.05%	-9.31%	37.59%	-28.94%	8.24%	-11.74%
Free Cash Flow Firm Q/Q Growth	32.01%	12.15%	2.99%	-23.24%	3.55%	18.05%	14.39%	3.84%	8.21%	6.57%
Invested Capital Q/Q Growth	-8.11%	-1.95%	-12.88%	13.60%	3.61%	-0.52%	-9.31%	6.06%	1.28%	5.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	74.02%	73.70%	73.65%	74.67%	74.70%	73.74%	74.06%	72.85%	72.51%	75.19%
EBITDA Margin	-56.28%	-70.38%	-75.64%	-74.65%	-74.19%	-86.44%	-95.46%	-110.41%	-91.92%	-103.99%
Operating Margin	-56.46%	-69.30%	-75.17%	-77.10%	-72.21%	-85.90%	-95.61%	-112.83%	-94.83%	-103.18%
EBIT Margin	-56.13%	-70.29%	-75.34%	-74.90%	-74.06%	-87.38%	-96.55%	-112.09%	-93.52%	-106.38%
Profit (Net Income) Margin	-55.44%	-69.38%	-73.74%	-72.92%	-72.04%	-84.33%	-94.19%	-109.12%	-92.60%	-104.96%
Tax Burden Percent	100.29%	101.38%	100.55%	101.37%	101.82%	100.40%	100.87%	100.79%	101.75%	100.00%
Interest Burden Percent	98.48%	97.36%	97.35%	96.05%	95.54%	96.13%	96.71%	96.59%	97.30%	98.67%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-146.92%	-166.82%	-172.55%	-149.89%	-145.03%	-166.80%	-177.73%	-187.48%	-163.18%	-181.88%
ROIC Less NNEP Spread (ROIC-NNEP)	-142.16%	-161.92%	-167.89%	-146.34%	-141.34%	-163.27%	-174.13%	-184.32%	-160.51%	-179.16%
Return on Net Nonoperating Assets (RNNOA)	110.76%	127.92%	134.55%	116.11%	116.49%	136.89%	148.14%	156.98%	140.33%	158.99%
Return on Equity (ROE)	-36.15%	-38.90%	-38.01%	-33.78%	-28.54%	-29.91%	-29.58%	-30.50%	-22.85%	-22.90%
Cash Return on Invested Capital (CROIC)	-167.76%	-177.22%	-179.61%	-165.99%	-180.27%	-184.51%	-190.60%	-182.63%	-208.27%	-221.45%
Operating Return on Assets (OROA)	-27.62%	-31.63%	-31.55%	-29.89%	-27.38%	-29.26%	-28.86%	-30.35%	-23.41%	-24.61%
Return on Assets (ROA)	-27.27%	-31.22%	-30.88%	-29.10%	-26.64%	-28.24%	-28.15%	-29.54%	-23.17%	-24.29%
Return on Common Equity (ROCE)	-36.15%	-38.90%	-38.01%	-33.78%	-28.54%	-29.91%	-29.58%	-30.50%	-22.85%	-22.90%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-60.80%	-57.19%	-53.15%	0.00%	-48.70%	-45.17%	-40.96%	0.00%	-35.26%
Net Operating Profit after Tax (NOPAT)	-9.39	-9.89	-11	-10	-9.74	-11	-12	-11	-10	-9.75
NOPAT Margin	-39.52%	-48.51%	-52.62%	-53.97%	-50.54%	-60.13%	-66.93%	-78.98%	-66.38%	-72.22%
Net Nonoperating Expense Percent (NNEP)	-4.76%	-4.90%	-4.66%	-3.54%	-3.69%	-3.53%	-3.60%	-3.15%	-2.66%	-2.72%
Return On Investment Capital (ROIC_SIMPLE)	-7.64%	-	-	-	-6.26%	-	-	-	-	-
Cost of Revenue to Revenue	25.98%	26.30%	26.35%	25.33%	25.30%	26.26%	25.94%	27.15%	27.49%	24.81%
SG&A Expenses to Revenue	113.64%	124.64%	121.80%	129.44%	126.69%	135.75%	136.46%	156.42%	142.03%	146.03%
R&D to Revenue	16.84%	18.36%	27.02%	22.33%	20.21%	23.89%	33.21%	29.26%	25.30%	32.34%
Operating Expenses to Revenue	130.47%	143.01%	148.82%	151.77%	146.90%	159.64%	169.67%	185.68%	167.33%	178.37%
Earnings before Interest and Taxes (EBIT)	-13	-14	-16	-14	-14	-15	-17	-16	-14	-14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-14	-16	-14	-14	-15	-16	-16	-14	-14
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.12	3.46	2.43	3.21	4.13	3.12	3.69	2.92	2.05	3.80
Price to Tangible Book Value (P/TBV)	3.21	3.54	2.49	3.28	4.21	3.18	3.76	2.98	2.08	3.86
Price to Revenue (P/Rev)	3.20	4.09	3.21	4.87	7.11	6.06	8.16	7.33	5.88	11.95
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.58	10.97	7.14	10.04	16.53	12.61	16.61	11.86	7.71	20.27
Enterprise Value to Revenue (EV/Rev)	2.43	3.20	2.20	3.72	5.74	4.48	6.33	5.27	3.45	9.26
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.43	0.40	0.37	0.34	0.31	0.30	0.28	0.26	0.11	0.11
Long-Term Debt to Equity	0.40	0.40	0.37	0.29	0.30	0.30	0.28	0.26	0.11	0.08
Financial Leverage	-0.78	-0.79	-0.80	-0.79	-0.82	-0.84	-0.85	-0.85	-0.87	-0.89
Leverage Ratio	1.67	1.60	1.56	1.44	1.36	1.34	1.33	1.30	1.24	1.23
Compound Leverage Factor	1.64	1.56	1.51	1.38	1.30	1.29	1.28	1.26	1.20	1.21
Debt to Total Capital	30.23%	28.39%	26.88%	25.20%	23.94%	22.85%	21.75%	20.57%	10.11%	9.61%
Short-Term Debt to Total Capital	2.58%	0.08%	0.07%	3.54%	1.39%	0.06%	0.05%	0.05%	0.05%	2.79%
Long-Term Debt to Total Capital	27.65%	28.31%	26.82%	21.66%	22.56%	22.80%	21.70%	20.52%	10.06%	6.82%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	69.77%	71.61%	73.12%	74.80%	76.06%	77.15%	78.25%	79.43%	89.89%	90.39%
Debt to EBITDA	-0.65	-0.64	-0.63	-0.62	-0.60	-0.60	-0.61	-0.64	-0.30	-0.31
Net Debt to EBITDA	1.12	1.21	1.31	1.39	1.52	1.66	1.83	2.03	2.25	2.50
Long-Term Debt to EBITDA	-0.59	-0.64	-0.63	-0.53	-0.57	-0.60	-0.61	-0.64	-0.30	-0.22
Debt to NOPAT	-0.92	-0.91	-0.90	-0.89	-0.86	-0.85	-0.87	-0.90	-0.42	-0.44
Net Debt to NOPAT	1.60	1.74	1.87	1.98	2.18	2.34	2.58	2.85	3.17	3.54
Long-Term Debt to NOPAT	-0.84	-0.91	-0.89	-0.76	-0.81	-0.85	-0.86	-0.89	-0.42	-0.31
Altman Z-Score	-0.86	-0.08	-0.46	1.41	2.67	1.87	3.18	2.85	3.20	8.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.58	7.70	8.97	6.95	6.50	7.19	8.42	10.62	9.14	8.44
Quick Ratio	4.69	6.53	7.71	5.95	5.58	6.18	7.38	9.43	8.10	7.57
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-6.81	-10	-11	-12	-9.54	-9.89	-12	-14	-15	-16
Operating Cash Flow to CapEx	-6,063.06%	-1,740.87%	-1,230.28%	-2,615.30%	-4,224.50%	-1,753.25%	-14,612.96%	-20,727.87%	-5,571.59%	-3,830.47%
Free Cash Flow to Firm to Interest Expense	-8.09	-11.24	-12.80	-13.31	-10.55	-11.07	-13.96	-24.68	-40.83	-55.83
Operating Cash Flow to Interest Expense	-7.99	-8.13	-6.48	-13.36	-9.35	-9.66	-9.13	-22.14	-27.31	-37.37
Operating Cash Flow Less CapEx to Interest Expense	-8.12	-8.59	-7.00	-13.87	-9.57	-10.21	-9.20	-22.25	-27.81	-38.34
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.49	0.45	0.42	0.40	0.37	0.33	0.30	0.27	0.25	0.23
Accounts Receivable Turnover	6.64	7.29	7.65	7.81	6.61	7.49	7.37	7.66	7.04	7.35
Inventory Turnover	1.29	1.24	1.21	1.14	1.15	1.09	0.92	0.89	0.89	0.85
Fixed Asset Turnover	24.16	22.50	21.73	16.76	15.75	14.43	13.26	12.20	11.29	10.79
Accounts Payable Turnover	8.18	5.28	7.11	6.24	11.01	5.92	6.43	5.29	8.26	3.68
Days Sales Outstanding (DSO)	54.94	50.08	47.71	46.74	55.23	48.74	49.53	47.62	51.83	49.68
Days Inventory Outstanding (DIO)	281.93	294.71	301.10	319.36	318.78	334.67	397.56	410.46	408.06	428.49
Days Payable Outstanding (DPO)	44.59	69.16	51.31	58.54	33.14	61.63	56.77	68.95	44.18	99.32
Cash Conversion Cycle (CCC)	292.27	275.63	297.50	307.56	340.87	321.78	390.32	389.14	415.70	378.85
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	21	23	24	27	24	23	23	25	24	24
Invested Capital Turnover	3.72	3.44	3.28	2.78	2.87	2.77	2.66	2.37	2.46	2.52
Increase / (Decrease) in Invested Capital	-2.58	0.13	0.47	1.58	-0.21	-0.74	0.56	2.61	4.42	6.22
Enterprise Value (EV)	204	254	168	272	394	290	384	302	185	481
Market Capitalization	268	325	246	355	488	393	495	421	315	621
Book Value per Share	$2.17	$2.40	$2.61	$2.86	$3.09	$3.31	$3.55	$3.82	$4.12	$4.39
Tangible Book Value per Share	$2.11	$2.34	$2.55	$2.80	$3.03	$3.24	$3.48	$3.76	$4.05	$4.32
Total Capital	123	131	138	148	156	163	171	181	171	181
Total Debt	37	37	37	37	37	37	37	37	17	17
Total Long-Term Debt	34	37	37	32	35	37	37	37	17	12
Net Debt	-65	-71	-78	-83	-94	-103	-111	-118	-130	-140
Capital Expenditures (CapEx)	0.11	0.42	0.47	0.45	0.20	0.49	0.05	0.06	0.18	0.28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	15	15	16	12	10	9.38	11	9.18	9.34
Debt-free Net Working Capital (DFNWC)	115	123	130	132	129	127	145	164	151	166
Net Working Capital (NWC)	112	123	130	127	127	127	145	164	150	161
Net Nonoperating Expense (NNE)	3.78	4.25	4.39	3.57	4.14	4.28	4.69	4.38	4.04	4.42
Net Nonoperating Obligations (NNO)	-65	-71	-78	-83	-94	-103	-111	-118	-130	-140
Total Depreciation and Amortization (D&A)	-0.04	-0.02	-0.06	0.05	-0.03	0.17	0.19	0.24	0.25	0.32
Debt-free, Cash-free Net Working Capital to Revenue	15.81%	18.53%	19.78%	21.24%	17.59%	15.82%	15.47%	19.58%	17.11%	17.98%
Debt-free Net Working Capital to Revenue	137.23%	154.76%	169.69%	180.66%	188.45%	195.87%	239.05%	286.19%	280.55%	320.47%
Net Working Capital to Revenue	133.44%	154.64%	169.57%	173.50%	185.31%	195.73%	238.90%	286.04%	280.39%	310.76%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.36)	($0.39)	($0.36)	($0.36)	($0.39)	($0.43)	($0.42)	($0.38)	($0.38)
Adjusted Weighted Average Basic Shares Outstanding	39.11M	39.28M	38.94M	38.64M	37.97M	38.12M	37.82M	37.57M	37.10M	37.19M
Adjusted Diluted Earnings per Share	($0.33)	($0.36)	($0.39)	($0.36)	($0.36)	($0.39)	($0.43)	($0.42)	($0.38)	($0.38)
Adjusted Weighted Average Diluted Shares Outstanding	39.11M	39.28M	38.94M	38.64M	37.97M	38.12M	37.82M	37.57M	37.10M	37.19M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	39.80M	39.49M	39.15M	38.82M	38.54M	38.31M	38.03M	37.75M	37.65M	37.41M
Normalized Net Operating Profit after Tax (NOPAT)	-9.39	-9.89	-11	-10	-9.74	-11	-12	-11	-10	-9.75
Normalized NOPAT Margin	-39.52%	-48.51%	-52.62%	-53.97%	-50.54%	-60.13%	-66.93%	-78.98%	-66.38%	-72.22%
Pre Tax Income Margin	-55.28%	-68.44%	-73.34%	-71.94%	-70.75%	-84.00%	-93.38%	-108.26%	-91.00%	-104.96%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-15.84	-16.08	-17.57	-15.99	-15.79	-17.29	-19.21	-28.53	-40.18	-50.22
NOPAT to Interest Expense	-11.15	-11.10	-12.27	-11.52	-10.78	-11.90	-13.32	-20.11	-28.52	-34.10
EBIT Less CapEx to Interest Expense	-15.98	-16.55	-18.10	-16.50	-16.01	-17.84	-19.28	-28.64	-40.67	-51.20
NOPAT Less CapEx to Interest Expense	-11.29	-11.57	-12.80	-12.03	-11.00	-12.45	-13.38	-20.21	-29.01	-35.07
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.05%	0.00%

Frequently Asked Questions About Pulmonx's Financials

When does Pulmonx's fiscal year end?

According to the most recent income statement we have on file, Pulmonx's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pulmonx's net income changed over the last 2 years?

Pulmonx's net income appears to be on a downward trend, with a most recent value of -$56.39 million in 2024, falling from -$58.92 million in 2022. The previous period was -$60.84 million in 2023. View Pulmonx's forecast to see where analysts expect Pulmonx to go next.

What is Pulmonx's operating income?

Pulmonx's total operating income in 2024 was -$57.70 million, based on the following breakdown:

Total Gross Profit: $62.00 million
Total Operating Expenses: $119.71 million

How has Pulmonx revenue changed over the last 2 years?

Over the last 2 years, Pulmonx's total revenue changed from $53.66 million in 2022 to $83.79 million in 2024, a change of 56.1%.

How much debt does Pulmonx have?

Pulmonx's total liabilities were at $77.04 million at the end of 2024, a 29.6% increase from 2023, and a 94.2% increase since 2022.

How much cash does Pulmonx have?

In the past 2 years, Pulmonx's cash and equivalents has ranged from $70.91 million in 2024 to $101.74 million in 2022, and is currently $70.91 million as of their latest financial filing in 2024.

How has Pulmonx's book value per share changed over the last 2 years?

Over the last 2 years, Pulmonx's book value per share changed from 4.12 in 2022 to 2.17 in 2024, a change of -47.2%.

Related Companies

This page (NASDAQ:LUNG) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Financials

Frequently Asked Questions About Pulmonx's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Financials

Annual Income Statements for Pulmonx

Quarterly Income Statements for Pulmonx

Annual Cash Flow Statements for Pulmonx

Quarterly Cash Flow Statements for Pulmonx

Annual Balance Sheets for Pulmonx

Quarterly Balance Sheets for Pulmonx

Annual Metrics And Ratios for Pulmonx

Quarterly Metrics And Ratios for Pulmonx

Frequently Asked Questions About Pulmonx's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools